SYnAbs' vision is to fill the gap in the marketplace for innovative antibodies against poor immunogenic compounds and complex antigens. Targeting steroids, peptides, small molecules, toxins, lipids and polysaccharides, SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat and guinea pig species to generate unique monoclonal antibodies of extreme specificity and higher affinity.
Unique monoclonal antibody products
Custom monoclonal antibody services
Maximizing the success rate and the quality of the mAbs generated in rats and guinea pigs. Meet with multiple species antibody expert!
The benefits of our technology?
- Extreme specificity
- Higher affinity
- Excellent results for small, difficult and poor immunogenic antigens
- Additional epitope recognition
- Access to the lymph nodes
- Rat Fc close to the human one
- Ideal for mice antigens
Our 2019 agenda
| When? | Where? |
|
February 1st Feb 4th - Feb 5th Feb 21st - Feb 22nd March 11th - March 13th April 2nd - April 5th May 9th May 21st - May 23rd June 18th - June 19th Aug 3rd - Aug 8th Sep 10th - Sep 11th Sep 10th - Sep 12th Oct 15th - Oct 17th Nov 11th - Nov 16th Nov 12th - Nov 16th Dec 10th - Dec 11th |
Antwerpen, Belgium, Belgian Association of Cancer Research Toulouse, France, Buzz4Bio mAb production Leuven, Belgium, Life-on-chip Alpach, Austria, The Alpach Workwhop Vienna, Austria, BioProcess International Ghent, Belgium, Knowledge for Growth Hannover, Germany, Labvolution/Biotechnica Oxford, United Kingdom, Pivotal Scientific Anaheim, USA, AACC Leuven, Belgium, Cellular heterogeneity in Central Nervous System Copenhagen, Denmark, Nordic Life Science Days Bale, Switzerland, Antibody European Congress Dusseldorf, Germany, MEDICA Lisbon, Portugal, PEGS Marseille, France, Biofit |